Shortages of women in rural areas occur in many highly urbanized countries. Rural East Germany is an ideal case for studying this phenomenon because of its low adult sex ratio (ASR)-men greatly outnumber women-coupled with high outmigration among young adults. This study identifies how internal migration between rural and urban areas contributes to the shortage of young adult women. We use data on inter-county migration flows (for years 2002-21) to decompose the impacts of migration flows on ASRs. We find that the low ASRs in rural East Germany have been driven by sex-selective migration. In the early 2000s the main destination of sex-selective outflows was West Germany, while in the 2010s urban areas in East Germany were the key destinations. We find that moves among 18-24-year-olds increased the shortage of women in the rural population, whereas moves among 25-29-year-olds contributed to more balanced ASRs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/00324728.2024.2382154 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of Antihyperglycemic Medications Among US People with Limited English Proficiency.
J Gen Intern Med
January 2025
Department of Family Medicine, College of Human Medicine, Michigan State University, East Lansing, MI, 48824, USA.
Background: Language barriers can impact pharmaceutical disease management leading to potential health disparities among limited English proficiency (LEP) people with diabetes mellitus (DM) in the United States (US).
Objective: To assess the use of antihyperglycemic medications and estimate their impact on glycemic control by LEP status.
Design: Cross-sectional design.
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
Lancet
January 2025
Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.
Background: CheckMate 8HW prespecified dual primary endpoints, assessed in patients with centrally confirmed microsatellite instability-high or mismatch repair-deficient status: progression-free survival with nivolumab plus ipilimumab compared with chemotherapy as first-line therapy and progression-free survival with nivolumab plus ipilimumab compared with nivolumab alone, regardless of previous systemic treatment for metastatic disease. In our previous report, nivolumab plus ipilimumab showed superior progression-free survival versus chemotherapy in first-line microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer in the CheckMate 8HW trial. Here, we report results from the prespecified interim analysis for the other primary endpoint of progression-free survival for nivolumab plus ipilimumab versus nivolumab across all treatment lines.
View Article and Find Full Text PDFStrengthening Policy Relevance of Wastewater-Based Surveillance for Antimicrobial Resistance.
Environ Sci Technol
January 2025
University of Warmia and Mazury in Olsztyn, Department of Water Protection Engineering and Environmental Microbiology, Prawochenskiego 1, Olsztyn 10-790, Poland.
Net Benefit of Early Anticoagulation for Stroke With Atrial Fibrillation: Post Hoc Analysis of the ELAN Randomized Clinical Trial.
JAMA Netw Open
January 2025
Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Importance: The net clinical effect of early vs later direct oral anticoagulant (DOAC) initiation after atrial fibrillation-associated ischemic stroke is unclear.
Objective: To investigate whether early DOAC treatment is associated with a net clinical benefit (NCB).
Design, Setting, And Participants: This was a post hoc analysis of the Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation (ELAN) open-label randomized clinical trial conducted across 103 sites in 15 countries in Europe, the Middle East, and Asia between November 6, 2017, and September 12, 2022, with a 90-day follow-up.
Assessing Preferences of Patients with Chronic Spontaneous Urticaria for Injectable Treatment Profiles.
Patient
January 2025
Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Background: In the context of injectable biologic products approved or in development for chronic spontaneous urticaria (CSU), it is important to capture which treatment attributes matter most to patient and what trade-offs patients are willing to make.
Objectives: The CHOICE-CSU study aimed to quantify patient preferences toward injectable treatment attributes among patients with CSU, inadequately controlled by H1-antihistamines.
Methods: This was a two-phase cross-sectional patient preference study in adult patients with a diagnosis of CSU, inadequately controlled by H1-antihistamines.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!